ReviewCurrent nutrition reports2026
Artificial Sweeteners and Gut Microbiota: Mechanistic Insights and Implications for Metabolic Health.
Review in Current nutrition reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mutual Influence of Sucralose and Bisphenol A on Biological and Neurobehavioral Action inInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewArtificial sweeteners (ASs) are widely used as sugar substitutes to reduce caloric intake. Emerging evidence indicates that these compounds are not metabolically inert and can alter gut microbiota composition and downstream metabolic regulation. This review synthesizes recent mechanistic and clinical evidence on how commonly used ASs-particularly sucralose, saccharin, acesulfame-K, aspartame, and steviol glycosides-modulate intestinal microbiota. RECENT
findingsExperimental and human studies show that AS exposure is associated with alterations in microbial diversity, short-chain fatty acid (SCFA) production, and gut barrier integrity. These alterations are linked to changes in glucose homeostasis, insulin sensitivity, and energy metabolism. Proposed mechanisms include modulation of nutrient-sensing G-protein-coupled receptors, interference with bile acid metabolism, and receptor-independent activation of intracellular signaling pathways such as PI3K/Akt and mTORC1. Notably, responses in human studies appear highly individualized and dose-dependent, highlighting substantial interindividual variability. This review integrates microbiome, metabolic, and mechanistic perspectives to identify areas of emerging consensus, conflicting results, and critical research gaps in AS-microbiota-metabolism interactions. Current evidence suggests that ASs can modulate host metabolism through both microbiota-dependent and independent mechanisms. These findings have direct implications for clinical dietary guidance and risk stratification, particularly among individuals with obesity, insulin resistance, or other metabolic disorders.
Indexed as
Identifiers
42142239What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.